Medigen Biotechnology Corporation operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Medigen Biotechnology with three other
companies in this sector in Taiwan:
Genomics Biosci &Tech Co Ltd
sales of 439.53 million Taiwanese Dollars [US$14.25 million]
Taigen Biopharmaceuticals Holdings Ltd
(553.21 million Taiwanese Dollars [US$17.94 million]
of which 100%
was Medical Development), and
Sofiva Genomics Co Ltd
(423.94 million Taiwanese Dollars [US$13.75 million]
Medigen Biotechnology reported sales of 457.78 million Taiwanese Dollars (US$14.85 million)
December of 2017.
increase of 14.5%
versus 2016, when the company's sales were 399.89 million Taiwanese Dollars.
Sales of Nucleic Acid Test saw an increase
that was more than double the company's growth rate: sales were up
32.9% in 2017, from
76.02 million Taiwanese Dollars to 101.00 million Taiwanese Dollars.